Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

8 terminated/withdrawn out of 40 trials

Success Rate

78.4%

-8.1% vs industry average

Late-Stage Pipeline

30%

12 trials in Phase 3/4

Results Transparency

3%

1 of 29 completed trials have results

Key Signals

2 recruiting1 with results8 terminated

Enrollment Performance

Analytics

Phase 1
15(42.9%)
Phase 3
12(34.3%)
Phase 2
7(20.0%)
Early Phase 1
1(2.9%)
35Total
Phase 1(15)
Phase 3(12)
Phase 2(7)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (40)

Showing 20 of 40 trials
NCT04368559Phase 3Completed

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Role: lead

NCT05432375Early Phase 1Completed

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

Role: lead

NCT06794554Phase 2Recruiting

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

Role: lead

NCT05534529Phase 1Terminated

Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

Role: lead

NCT05835479Phase 2Recruiting

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Role: lead

NCT03345485Phase 1Completed

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Role: lead

NCT02576496Phase 1Completed

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Role: lead

NCT05072249Unknown

European Cohort Study of the Effectiveness of Take Home Naloxone

Role: collaborator

NCT03789630Completed

Continuous Monitoring of Physiology and Self-reported Pain Score Amongst Post-surgical Knee Patients

Role: collaborator

NCT00563056Phase 3Completed

An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma

Role: lead

NCT00475813Phase 3Completed

Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma

Role: lead

NCT01511367Phase 3Completed

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

Role: lead

NCT01099722Phase 3Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Role: lead

NCT00734318Phase 3Completed

Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma

Role: lead

NCT00626600Phase 3Terminated

A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion

Role: lead

NCT00476073Phase 3Completed

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Role: lead

NCT01946620Phase 3Completed

A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

Role: lead

NCT00995800Phase 2Completed

Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma

Role: lead

NCT02063139Phase 2Completed

Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.

Role: lead

NCT00947466Phase 1Terminated

A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain

Role: lead